相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Gini coefficient: A new way to express selectivity of kinase inhibitors against a family of kinases
Piotr P. Graczyk
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Marcus Bantscheff et al.
NATURE BIOTECHNOLOGY (2007)
Molecular basis for specificity in the druggable kinome: sequence-based analysis
Jianping Chen et al.
BIOINFORMATICS (2007)
Sorafenib in renal cell carcinoma
Keith T. Flaherty
CLINICAL CANCER RESEARCH (2007)
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation
Francis J. Giles et al.
BLOOD (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Mechanisms of drug inhibition of signalling molecules
Judith S. Sebolt-Leopold et al.
NATURE (2006)
An efficient rapid system for profiling the cellular activities of molecular libraries
JS Melnick et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding
FB Sheinerman et al.
JOURNAL OF MOLECULAR BIOLOGY (2005)
Roscovitine targets, protein kinases and pyridoxal kinase
S Bach et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
TA Carter et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Features of selective kinase inhibitors
ZA Knight et al.
CHEMISTRY & BIOLOGY (2005)
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma
S Trudel et al.
BLOOD (2005)
A small molecule-kinase interaction map for clinical kinase inhibitors
MA Fabian et al.
NATURE BIOTECHNOLOGY (2005)
Kinomics-structural biology and chemogenomics of kinase inhibitors and targets
M Vieth et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2004)
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells
ER Wood et al.
CANCER RESEARCH (2004)
Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
LJ Lombardo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition
JF Ohren et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
The specificities of protein kinase inhibitors: an update
J Bain et al.
BIOCHEMICAL JOURNAL (2003)
Discovery of 5-[5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase
L Sun et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
The protein kinase complement of the human genome
G Manning et al.
SCIENCE (2002)
Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer
LF Allen et al.
SEMINARS IN ONCOLOGY (2002)
Design and discovery of small molecules targeting Raf-1 kinase
TB Lowinger et al.
CURRENT PHARMACEUTICAL DESIGN (2002)
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents
MJ Morin
ONCOGENE (2000)
分享论文
